| Reliable segregation of survival under immunotherapy in NSCLC using simple clinical parameters |
8. Petros Christopoulos |
Michael Thomas |
| Oncol Res Treat 49 (suppl.1): 193-4 |
Abstract |
2026 |
|
Thorakale Onkologie
|
|
|
| www.doi.org/10.1159/000550849 |
|
|
| Treatment patterns, outcome and QoL of ES-SCLC patients receiving third-line therapy – Data from the German CRISP Registry (AIO-TRK-0315) |
7. Maximilian Rost |
Martin Sebastian |
| Oncol Res Treat 49 (suppl.1): 194 |
Abstract |
2026 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| www.doi.org/10.1159/000550849 |
|
|
| Impact of Private versus Statutory Health Insurance Status on Quality of Care and Clinical outcomes in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer – Data from the German CRISP Registry (AIO-TRK-0315) |
Fabian Acker |
Martin Sebastian |
| Oncol Res Treat 49 (suppl.1): 247-8 |
Abstract |
2026 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| www.doi.org/10.1159/000550849 |
|
|
| Full cohort analysis of response and 60 day safety from the multicenter ROSE Study: Radiation during Osimertinib Treatment Safety and Efficacy Cohort |
Amanda Tufman |
Diego Kauffmann-Guerrero |
| Oncol Res Treat 49 (suppl.1): 200 |
Abstract |
2026 |
|
Thorakale Onkologie
|
ROSE |
|
| www.doi.org/10.1159/000550849 |
|
|
| Final analysis of the phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of checkpoint-inhibitor + axitinib in first line therapy (PREPARE; AIO-NZK-0115/ass; IAG-N) |
Viktor Grünwald |
Philipp Ivanyi |
| Oncol Res Treat 49 (suppl.1): 252 |
Abstract |
2026 |
|
Nierenzellkarzinom
|
PREPARE |
AIO-NZK-0115/ass |
| www.doi.org/10.1159/000550849 |
|
|
| Adjuvant Chemotherapy Alone or Combined with Atezolizumab in Patients with Stage III Deficient DNA Mismatch Repair (dMMR) Colon Cancer – Results of the Randomized ATOMIC Trial (Alliance A021502/AIO-KRK-0317) |
Dirk Arnold |
Frank Sinicrope |
| Oncol Res Treat 49 (suppl.1): 11-2 |
Abstract |
2026 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
ATOMIC |
AIO-KRK-0317 |
| www.doi.org/10.1159/000550849 |
|
|
| Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer |
Frank A. Sinicrope |
Jeffrey A. Meyerhardt |
| N Engl J Med 394(12): 1155-66 |
Vollpublikation |
2026 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
Atomic |
|
| www.doi.org/10.1056/NEJMoa2507874 |
|
|
| Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung – An AIO phase Ib/II trial |
Martin Reck |
Martin Sebastian |
| Lung Cancer 214 |
Vollpublikation |
2026 |
|
Thorakale Onkologie
|
|
|
| www.doi.org/10.1016/j.lungcan.2026.109318 |
|
|
| Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216) |
Lutz MP |
Karthaus M |
| Br J Cancer 134:85-91 |
Vollpublikation |
2026 |
|
Pankreaskarzinom
|
|
AIO-PAK-0216 |
| doi.org/10.1038/s41416-025-03188-x |
|
|
| Interim Analysis of pulmonary tolerability from the multicenter ROSE Study: Radiation during Osimertinib Treatment Safety and Efficacy Cohort |
Amanda Tufman |
Diego Kauffmann-Guerrero |
| Eur Respir J 66 (suppl 69): PA6062 |
Poster |
2025 |
|
Thorakale Onkologie
|
ROSE |
|
| www.doi.org/10.1183/13993003.congress-2025.PA6062 |
|
|
